Friederike Wunsch
Friederike Wunsch has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Gerhard Wolber
Molecular Design Group, Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy Freie Universität Berlin Berlin Germany
3 shared publications - Marcel Bermudez
Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany
3 shared publications - Carsten Hoffmann
Institute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, University Hospital Jena, Friedrich Schiller University Jena, Jena, Germany
2 shared publications - Ulrike Holzgrabe
Institute of Pharmacy and Food Chemistry, Julius-Maximilians-University of Würzburg, Würzburg, Germany
2 shared publications - Andy Chevigné
Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg
1 shared publication Ester Cassano
Immuno-Pharmacology and Interactomics, Department of Infection and Immunity
1 shared publication
Latest Publications
- 16 March 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (7) , 4049-4057
Dynamic Pharmacophores Unveil Binding Mode Ensembles for Classical Partial Agonists at the M2 Receptor
For the prototypical M2 receptor, it has been previously demonstrated that dualsteric partial agonists can stabilize both active and inactive receptor states, but it remains unclear whether orthosteric partial agonists have a similar mechanism. Here, we apply dynamic pharmacophore models to unveil binding mode ensembles for classical M2 partial agonists. We report correlations between the spatial distribution of lipophilic contacts and ligand efficacy and demonstrate the applicability of dynamic pharmacophore models to analyze subtle binding mode changes. Partial agonism at the receptor level can translate into clinically desired effects while reducing adverse side effects. Thus, an understanding of the underlying structural mechanism is essential for tailored drug design.
- 16 March 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (7) , 4049-4057
Dynamic Pharmacophores Unveil Binding Mode Ensembles for Classical Partial Agonists at the M2 Receptor
For the prototypical M2 receptor, it has been previously demonstrated that dualsteric partial agonists can stabilize both active and inactive receptor states, but it remains unclear whether orthosteric partial agonists have a similar mechanism. Here, we apply dynamic pharmacophore models to unveil binding mode ensembles for classical M2 partial agonists. We report correlations between the spatial distribution of lipophilic contacts and ligand efficacy and demonstrate the applicability of dynamic pharmacophore models to analyze subtle binding mode changes. Partial agonism at the receptor level can translate into clinically desired effects while reducing adverse side effects. Thus, an understanding of the underlying structural mechanism is essential for tailored drug design.
- 30 December 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (1) , 214-224
Deciphering Opioid Peptide Binding Modes at Atypical Chemokine Receptor 3
ACKR3 is a class A G protein-coupled receptor that is considered as an atypical chemokine receptor. It does not activate G proteins but efficiently recruits β-arrestin and mediates ligand internalization and was thus proposed as a scavenger receptor. Besides chemokines, ACKR3 internalizes a variety of endogenous opioid peptides, including adrenorphin and dynorphin A. By reducing their availability to the classical opioid receptors, ACKR3 is proposed to participate in the endogenous pain management system, suggesting it as a new potential target for a new class of analgesics. Available structural data for ACKR3 are focused on the binding of chemokines (e.g., CXCL12), but how opioid peptides bind at ACKR3 remains enigmatic. Here, we structurally modeled opioid peptide binding at ACKR3 with a focus on adrenorphin, its ACKR3 selective variant LIH383, and dynorphin A. By combining molecular dynamics simulations with pharmacophore analysis, we analyze the opioid peptides' binding modes and compare them with binding to classical opioid receptors (MOR, KOR, and DOR). We apply our model to rationally explain previously reported structure-activity relationships for adrenorphin derivatives, which also supports the model's validation. Moreover, we include in vitro ACKR3 mutational experiments on both the receptor and LIH383 to further strengthen our structural model. Taken together, we systematically combine in silico observations and in vitro readouts to contribute to the understanding of ACKR3's ligand binding profile and set the basis for further ACKR3 ligand development.
- 30 December 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (1) , 214-224
Deciphering Opioid Peptide Binding Modes at Atypical Chemokine Receptor 3
ACKR3 is a class A G protein-coupled receptor that is considered as an atypical chemokine receptor. It does not activate G proteins but efficiently recruits β-arrestin and mediates ligand internalization and was thus proposed as a scavenger receptor. Besides chemokines, ACKR3 internalizes a variety of endogenous opioid peptides, including adrenorphin and dynorphin A. By reducing their availability to the classical opioid receptors, ACKR3 is proposed to participate in the endogenous pain management system, suggesting it as a new potential target for a new class of analgesics. Available structural data for ACKR3 are focused on the binding of chemokines (e.g., CXCL12), but how opioid peptides bind at ACKR3 remains enigmatic. Here, we structurally modeled opioid peptide binding at ACKR3 with a focus on adrenorphin, its ACKR3 selective variant LIH383, and dynorphin A. By combining molecular dynamics simulations with pharmacophore analysis, we analyze the opioid peptides' binding modes and compare them with binding to classical opioid receptors (MOR, KOR, and DOR). We apply our model to rationally explain previously reported structure-activity relationships for adrenorphin derivatives, which also supports the model's validation. Moreover, we include in vitro ACKR3 mutational experiments on both the receptor and LIH383 to further strengthen our structural model. Taken together, we systematically combine in silico observations and in vitro readouts to contribute to the understanding of ACKR3's ligand binding profile and set the basis for further ACKR3 ligand development.
- Open Access
Dynamic pharmacophores unveil binding mode ensembles for classical partial agonists at the M 2 receptor
For the prototypic M 2 receptor it has been previously demonstrated that dualsteric partial agonists can stabilize both, active and inactive receptor states, but it remains unclear whether orthosteric partial agonists have a similar mechanism. Here, we apply dynamic pharmacophores to unveil binding mode ensembles for classical M 2 partial agonists. We report correlations between the spatial distribution of lipophilic contacts and ligand efficacy and demonstrate the applicability of dynamic pharmacophores to analyze subtle binding mode changes.
Open AccessDynamic pharmacophores unveil binding mode ensembles for classical partial agonists at the M 2 receptor
For the prototypic M 2 receptor it has been previously demonstrated that dualsteric partial agonists can stabilize both, active and inactive receptor states, but it remains unclear whether orthosteric partial agonists have a similar mechanism. Here, we apply dynamic pharmacophores to unveil binding mode ensembles for classical M 2 partial agonists. We report correlations between the spatial distribution of lipophilic contacts and ligand efficacy and demonstrate the applicability of dynamic pharmacophores to analyze subtle binding mode changes.